A working group from the Adult Treatment Panel III of the National Cholesterol Educational Program issued a revised algorithm for low-density lipoprotein (LDL)-cholesterol lowering in very high-risk cardiovascular disease patients. The rationale for these recommendations was primarily established from pooled analysis of multiple clinical trials of LDL-cholesterol-lowering therapies and limited data from an acute coronary syndrome trial. In the near future, the findings of these large-scale randomized trials designed to test the hypothesis that more aggressive LDL-cholesterol therapy is accompanied by fewer cardiovascular events than less aggressive LDL-cholesterol lowering therapy, will provide the evidence needed to support or refute these new recommendations. In this article, the authors suggest that an LDL-cholesterol level of less than 70 mg/dl is unattainable and not necessary for many high-risk patients. Furthermore, the potential risks associated with hIgh-dose statin agents in certain patients, such as the elderly, may outweigh these putative benefits.
- Cholesterol guidelines
- Clinical trials
- Low-density lipoprotein cholesterol
- Low-density lipoprotein particle number
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine